Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged new tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of alopecia areata, rheumatoid arthritis, lupus erythematosus, inflammation, allergy, cancer, metabolic diseases and transplant rejection, among other disorders.